With top-notch business, scientific research, and hospital trilogy resumes, Tian Hao leads the Yuan code gene for three years from 0 to 100,000.

"How far is humanity from curing cancer?" James sitting opposite. Watson is 90 years old and still shows a high level of interest in cancer precision medicine . In May of this year, he once again saw Tian Hao, and he still remembered to say: "I hope to develop cancer treatments that everyone can afford in China."

James. Watson and Tian Hao's many exchange photos (picture from the meta code gene)

James. Watson is known as the "father of DNA" and discovered the DNA double helix in the 1950s and won the Nobel Prize. Fifty years later, genetic technology developed on the basis of DNA research has become the darling of the times. In particular, the application of genetic technology in precision medicine has enabled humans to see the hope of conquering cancer.

Hope has gradually become a reality. In 2014, Tian Hao saved the life of a patient with advanced lung cancer with his own genetic testing technology. At the moment of "testimony to the miracle," Tian Yiyi decided to step out of the lab without hesitation, and let the technology in his hands help more patients to win the death. At the end of the year, the metacode gene jointly developed by Tian Hao and his partner was established in Beijing.

Three years later, the accurate medical service of the Yuan code gene has covered hundreds of hospitals, serving nearly 100,000 patients. This performance has made the low-key meta-code gene win the favor of well-known medical investor Feng Tang. After the two sides met only three times, CITIC Capital decided to lead the B round of financing of the metacode gene.

The day when CITIC Capital Investment was finalized was Tian Hao’s 37-year-old birthday. If he was involved in the genetic sequencing of the SARS virus during the SARS epidemic, he has been studying this field for 15 years. Now, Tian Hao and Yuan Zhen have more chips in their hands and have the opportunity to go further in the fight against cancer.

1. "96 hours"

At first, Tian Hao almost "missed" Feng Tang.

At the end of 2016, during the International Science Conference of the International Genomics Conference, Academician Yang Huanming, the chief scientist of the organizer of Huada Gene, recommended Tian Hao to the then special guest Feng Tang. At that time, Tian Hao missed a meeting with Feng Tang because he had to go to an important negotiation.

However, the two have since established contact. "In the later meeting, we talked from poetry and songs to philosophy of life, and then talked about precision medicine." "Wen Qing", who loves writing science, found that there are many common languages ​​with Feng Tang. Of course, the most important thing is that the two A consensus was reached on the business model and future development path of the metacode, so that cooperation was achieved by hitting the ball.

To promote the achievement of cooperation, Feng Huan and Tian Hao’s teacher Yang Huanming are also indispensable. Yang Huanming gave a lecture to Feng Tang during his work at Xiehe Medical University. He was also a tutor during his tenure at Ph.D. The time that followed Yang Huanming’s study played a key role in Tian’s later growth.

Feng Tang (left) and Tian Wei and their teacher Yang Huanming (middle) (picture from Yuan code gene)

The opportunity came from the SARS incident that swept the country.

The undergraduate is nearing the graduation stage, which coincides with the SARS incident. Tian Hao, who is doing a graduate internship at Huada, has the opportunity to participate in the decoding of the SARS gene. He witnessed the SRAS virus that caused social panic from sequencing, decoding, and development of diagnostic reagents, and then to Huada to distribute hundreds of thousands of vaccines to the people free of charge, which eased the spread of the epidemic.

From the time of obtaining the viral DNA, Huada measured the gene sequence of the SARS virus in a dozen hours, made a SARS test kit in 96 hours, and donated 300,000 copies to the National Atypical Pneumonia Command. SARS virus diagnostic kit. This "96 hours" experience opened up a new understanding of gene sequencing for Tian Hao.

After graduation, Tian Hao entered the work of Huada. With strong learning ability, Tian Hao masters new knowledge quickly, and his professional skills are also rapidly increasing in a short period of time. The diligent and tough Tian Hao in the bones soon began a new round of challenges - studying for genomics graduate students while working as a genomics expert, Academician Yang Huanming.

Yang Huanming was one of the founders of Huada Gene, and he was already famous in the United States. In 1997, Yang Huanming relied almost exclusively on personal relationships and reputation to secure 1% of the Human Genome Project for the Chinese team.

In 2003, the human genome sequencing work, which took 13 years, was completed, with a total investment of 4.2 billion US dollars. But it was at the earliest stage of genetic technology. Later developments showed that there will be tremendous changes in this field, and the choice of direction will determine the future growth space. Such a great change tested the young Tian Hao.

When Tian Hao began to pursue his Ph.D., the gene chip was fired and many scientific research results were also launched. Many research ideas on doctoral students in the same period as Tian Hao are also using gene chip technology to carry out genome research. However, after several rounds of experiments, he found that the gene chip actually has a big problem, and the future development is not optimistic.

In 2005, Next Generation Sequencing Technology (NGS) was introduced. What is different from the later technology, the entire industry has sung this new technology. Tian Hao believes that NGS has the advantages of data and high accuracy, so NGS has been chosen as the research direction of doctoral subjects.

The choice of the doctoral program actually means that Tian Hao has bet on his future career in the technical direction of NGS. As it turned out, his judgment at the time was quite far-sighted. Ten years later, NGS technology reduced the cost of gene sequencing from $100 million to $1,000.

2. "Employee No. 007"

During Tian Hao’s Ph.D., Huada’s genes finally survived the edge of early survival and were in a rapidly rising momentum.

Due to its outstanding performance in the Human Genome Project and the SARS incident, Huada Gene has won high-level attention and recognition. At that time, the Chinese Academy of Sciences and Huada Gene jointly established the Beijing Genomics Institute of the Chinese Academy of Sciences. The state also gave 90 formalities to the Huada Gene. Yang Huanming and Wang Jian even enjoyed the treatment of bureau-level cadres.

However, after a series of changes, Huada Gene decided to go south to Shenzhen in 2007. That was actually a choice to return to zero. Tian Hao decided to go south and became the No. 007 employee of Huada Gene.

Like the slightly legendary number of 007, Tian Hao contributed awesome performance in the next five years of Huada.

In 2009, Huada launched a 100,000 HLA bone marrow typing test program. At the time, traditional sequencing methods were costly and time consuming, and using traditional methods meant that profits were almost zero. Tian Hao’s research on NGS played an important role at this time.

In three months, Tian Hao led the team to develop the world's first commercial HLA typing system based on Next Generation Sequencing Technology (NGS) to meet the needs of bone marrow matching. And the new method, because it does not require manual interpretation, greatly improves the accuracy, saves 2/3 of the cost, and improves the efficiency. In the same year, it created tens of millions of profits for the company.

These achievements are not only due to his discovery of technology, but also his ability to transform technology.

In 2011, the mainstream technology for genetic screening was still the chip method. However, the chip method has a high price and a long cycle, and is not suitable for large-scale clinical promotion. This time, Tian Hao's team completed the whole process from project establishment, research and development to clinical application in just a few months. In the whole of Tianjin, the genetic testing technology for neonatal deafness gene screening project was completed. The detection of 10,000 newborns and the finding of dozens of children with congenital deafness make up for the possible missed detection of traditional hearing screening.

The project is not only the first large-scale genetic screening project based on NGS in China, but also brings tens of millions of production value per year to the company.

In the short time of working and reading in China University of China, Tian Hao, who was in his twenties, applied for more than 10 domestic and foreign patents and completed the first Asian human genome sequence map "Yanhuang No.1" and other doctoral research topics. It also guided and participated in large-scale international cooperation projects such as “Giant Panda Genomic Sequencing” and “Thousand Human Genome Project”, as well as a number of national “863” and “973” projects. While completing his studies, he also grew up from the technical staff, deputy director of research and development, all the way to the general manager of North China, and the general manager of Tianjin Huada.

Image from metacode gene

Tian Wei said that the Huada gene during the reconstruction period gave him a lot of experience. This not only helps him gain more and faster accumulation in professional technology, but more rarely, he has the opportunity to operate scientific research projects from the perspective of enterprise development. At this time, Tian Hao did not think of starting a business, but his performance in the Chinese gene has attracted the attention of two heavyweight scholars in Beijing.

3, "Running to death"

In the second decade of the 21st century, precision medicine based on genetic technology began to attract more and more attention around the world. In 2011, the concept of “precise medical care” has emerged in the United States. In 2015, US President Barack Obama proposed a precision medical plan, which set off a wave of precision medicine on a global scale.

Almost at the same time, China's top scientists have also seen the broad prospects for the application of genetic technology and embarked on implementation.

In 2012, he was invited by Professor Shi Yigong, the dean of the Life Science Academy of Tsinghua University. Tian Hao joined the Tsinghua University School of Medicine and was responsible for the preparation of the sequencing platform. His performance during this period also lived up to expectations.

During the preparation of the sequencing platform, Tian Hao led the team to complete a number of topics. One of the representative topics is the research project on “Microbial Composition of Haze in Beijing”. It not only analyzes the composition and source of microbes of smog pollutants, but also provides great reference value for the treatment of smog.

In the same period, Tian Hao was also invited by the Academician Zhao Yupei, Dean of Peking Union Medical College Hospital, to help the Concord Hospital to establish a translational medicine center.

At this time, Tian Hao thought that he would continue to follow the academic path and do scientific research in the university. Who once thought of "writing a turn", he made another choice. In Tian’s own words, “Life is sometimes a matter of a second.”

One day in 2014, Tian Hao received a call from a friend. A friend said that his teacher had advanced lung cancer. Because of his age, the hospital adopted a very conservative treatment method, which basically equaled the death penalty for the elderly. A friend asked him for help: "I heard that you are doing research that can detect tumor genes through peripheral blood. Can you use your technology to provide some help to teachers? Even if it is a little hope."

Tian Hao was hesitant to hear from a friend. Because at the time the technology was only in the laboratory stage, there was still a distance from clinical applications. But he couldn't bear to see his friend's only hope, and he and the team quickly designed a personalized detection program.

Fortunately, by testing, they found a mutation with a very low probability of occurrence, and this mutation happens to be the basis for medication. Thus, the test results instruct the doctor to determine a new medication regimen. After taking the medicine, the 72-year-old professor who was originally judged by the doctor to survive for only a few weeks, the tumor was reduced by 90%, successfully continuing life and improving the quality of life.

In that second, Tian Hao saw that technological progress can sometimes win the death. He realized that he should go out of the laboratory and turn the research results into industrial achievements, which will benefit more people in need. At the end of 2014, Tian Hao and his partner set up the “Yuan Code Gene” in Beijing, hoping to help more patients through the efforts of the team.

But entrepreneurship can't just rely on one passion, especially technology like genetic testing, which was still at a very early stage and the market is still immature. Finding the real needs and providing matching products is a rigorous test for start-ups. Tian Hao’s composite resume from business to academic institutions to medical institutions shows an advantage. He clearly knows the status quo and pain points in this field.

In the process of helping Peking Union Medical College Hospital to establish a translational medicine center, Tian Hao discovered the contradiction between the huge clinical needs and the limited clinical testing resources of the hospital, and the lack of talents in domestic hospitals.

Through the practical work experience in the hospital, Tian Wei believes that there are many restrictions on the implementation of precision medical projects in hospitals at this stage. The system requires the integration of multiple capabilities, not the recruitment of several technicians and the purchase of several devices. Tian Hao envisioned whether the hospital could provide a “one-stop” service that can be operated by itself in a non-outsourced form to help the hospital solve the current problems.

After the establishment of the meta-code gene, Tian Hao’s idea began to be implemented. He and the team pioneered a business model of building a precision medical testing center with the hospital, which not only provided the hospital with a complete set of solutions, but also helped the hospital to quickly solve the problem of insufficient precision medical support, and avoided the way of sending samples for testing. The risk of doctors and patients.

Practice has proved that Tian Hao’s idea has cut the pain points of the hospital. In the three years after the establishment of the metacode gene, their products were quickly recognized by the hospital, covering more than 100 hospitals and serving nearly 100,000 patients. After receiving investment from CITIC Capital, the Yuan code gene ranks among the top in the precision medical industry . The outstanding performance once again won a bigger stage for Tian Hao, and his future performance is still worth looking forward to.

High Class Vitamins

Vitamins are trace organic substances that humans and animals need from food to maintain normal physiological functions.It plays an important role in human growth, metabolism and development. Vitamins are not involved in building cells in the body, nor do they provide energy for the body.

We supply all kinds of high quality food grade, animal grade vitamins.

High Class Vitamins,Nicotinic Acid Vitamin,Riboflavin Vitamin B2,Blood Coagulation Vitamin

Allied Extracts Solutions , https://www.alliedadditives.com